SITC 2021 | Treating tumors with SYNB1891 to overcome anti-PD1 resistance

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, outlines SYNB1891, an investigational drug designed by Synlogic to drive an immune response for the intra-tumoral treatment of solid tumors and lymphoma. Once injected, SYNB1891 traffics into areas of low levels of oxygen and high levels of purine where it produces a cGAS/stimulator of interferon genes (STING) agonist. An induction of interferon responses based on the STING agonism has been noted when injected into tumors. The aim of treating tumors with SYNB1891 is to enhance innate immunity to potentially overcome resistance to anti-PD-1.